Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenylbutyrate, Dexamethasone and GM-CSF in Refractory/Relapsed t(8;21) AML
NCT00006240Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Oct 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium phenylbutyrate in acute myeloid leukemia (AML), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Objective Response (Complete Hematologic Remission Induction). Started Oct 2000; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00006240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006240.